Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Reverse Stock Split Announcement: Channel Therapeutics Corporation has announced a 10-for-one reverse stock split of its common stock, effective July 1, 2025, to increase share price and meet NYSE American listing requirements in connection with a merger and capital raise.
Company Focus and Future Plans: The company specializes in developing non-opioid pain treatments and will change its trading name to "Pelthos Therapeutics Inc." following the reverse split, while maintaining its current stock symbol "CHRO" until the merger is completed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
